Website profile

pharmiweb.com

PharmiWeb.com - Global pharma news from the pharmaceutical industry, biotech, clinical research, life science & healthcare. Pharma Events Listings, Pharma Company Directory & pharma jobs.

  • 713articles · 180d
  • 3+ mon agolatest article
  • Mar 17, 2026earliest in window
  • 94%with images
  • 311avg words
articles per day
Categories
  • Economy, Business & Finance 360
  • Medical 349
  • Health & Wellness 296
  • Finance & Business 273
  • Business & Industrial 207
  • Health 178
  • News 134
  • Science & Technology 111

Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

PharmiWeb.com
pharmiweb.com > press-release > 2026-05-14 > triple-hair-expands-global-phase-iii-program-for-th07-with-launch-of-500-patient-trial-in-india

Triple Hair Expands Global Phase III Program for TH07 with Launch of 500-Patient Trial in India

3+ mon, 4+ week ago   (315+ words) MONTRÉAL--(BUSINESS WIRE)--Triple Hair Group Inc. (“Triple Hair” or the “Company”), a company specializing in the development of innovative treatments for androgenic alopecia (pattern baldness), today announced the initiation of its Phase III clinical trial in India evaluating TH07, the…...

PharmiWeb.com
pharmiweb.com > press-release > 2026-04-02 > triple-hair-doses-first-patient-in-phase-iii-clinical-trial-in-canada-for-male-androgenic-alopecia

Triple Hair Doses First Patient in Phase III Clinical Trial in Canada for Male Androgenic Alopecia

5+ mon, 1+ week ago   (315+ words) MONTRÉAL--(BUSINESS WIRE)--Triple Hair Group Inc. (“Triple Hair” or the “Company”), a company specializing in the development of innovative treatments for androgenic alopecia (pattern baldness), today announced that the first patient has been dosed in its Phase III clinical…...